FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2075849809> ?p ?o ?g. }

• W2075849809 endingPage "1188" @default.
• W2075849809 startingPage "1181" @default.
• W2075849809 abstract "Products of proto-oncogenes c-MET and RON belong to a subfamily of receptor tyrosine kinases that contribute significantly to tumorigenic progression. In primary tumors, altered c-MET/RON expression transduces signals regulating invasive growth that is characterized by cell migration and matrix invasion. These pathogenic features provide the basis for targeting c-MET/RON in cancer therapy. In the last decade, various approaches have been investigated to suppress c-MET/RON-transduced oncogenesis. Among the therapeutics developed, monoclonal antibodies (mAbs) and small-molecule inhibitors (SMIs) have emerged as promising candidates. The mechanism of these therapeutic candidates is the disruption of tumor dependency on c-MET/RON signals for survival. The mAbs specific to hepatocyte growth factor (AMG102) and c-MET (MetMAb) are both humanized and able to block c-MET signaling, leading to inhibition of tumor cell proliferation in vitro and inhibition of tumor growth in xenograft models. The mAb AMG102 neutralizes hepatocyte growth factor and enhances the cytotoxicity of various chemotherapeutics to tumors in vivo. AMG102 is currently in phase II clinical trials for patients with advanced solid tumors. IMC-41A40 and Zt/f2 are RON-specific mAbs that down-regulate RON expression and inhibit ligand-induced phosphorylation. Both mAbs inhibit tumor growth in mice mediated by colon and pancreatic cancer cells. SMIs specific to c-MET (ARQ107 and PF-02341066) are in various phases of clinical trials. Therapeutic efficacy has also been observed with dual inhibitors such as Compound I, which is specific to c-MET/RON. However, a potential issue is the emergence of acquired resistance to these inhibitors. Clearly, development of c-MET/RON therapeutics provides opportunities and challenges for combating cancer in the future." @default.
• W2075849809 created "2016-06-24" @default.
• W2075849809 creator A5018692209 @default.
• W2075849809 creator A5019881260 @default.
• W2075849809 creator A5050339289 @default.
• W2075849809 creator A5050878902 @default.
• W2075849809 creator A5089011631 @default.
• W2075849809 date "2010-08-09" @default.
• W2075849809 modified "2023-10-17" @default.
• W2075849809 title "Potential therapeutics specific to c-MET/RON receptor tyrosine kinases for molecular targeting in cancer therapy" @default.
• W2075849809 cites W1542053886 @default.
• W2075849809 cites W1639582946 @default.
• W2075849809 cites W1963720869 @default.
• W2075849809 cites W1965977814 @default.
• W2075849809 cites W1966828606 @default.
• W2075849809 cites W1972514043 @default.
• W2075849809 cites W1977889545 @default.
• W2075849809 cites W1985264867 @default.
• W2075849809 cites W1986159749 @default.
• W2075849809 cites W1996160829 @default.
• W2075849809 cites W1997923564 @default.
• W2075849809 cites W1998971866 @default.
• W2075849809 cites W2003278673 @default.
• W2075849809 cites W2003463361 @default.
• W2075849809 cites W2010368333 @default.
• W2075849809 cites W2011582582 @default.
• W2075849809 cites W2017890169 @default.
• W2075849809 cites W2029916671 @default.
• W2075849809 cites W2030283269 @default.
• W2075849809 cites W2030699054 @default.
• W2075849809 cites W2033247490 @default.
• W2075849809 cites W2038056960 @default.
• W2075849809 cites W2040665709 @default.
• W2075849809 cites W2042944401 @default.
• W2075849809 cites W2050119840 @default.
• W2075849809 cites W2057234572 @default.
• W2075849809 cites W2058482794 @default.
• W2075849809 cites W2058522541 @default.
• W2075849809 cites W2062538312 @default.
• W2075849809 cites W2073597573 @default.
• W2075849809 cites W2077224394 @default.
• W2075849809 cites W2077804275 @default.
• W2075849809 cites W2084839458 @default.
• W2075849809 cites W2087857088 @default.
• W2075849809 cites W2087898932 @default.
• W2075849809 cites W2089357665 @default.
• W2075849809 cites W2089766601 @default.
• W2075849809 cites W2091068407 @default.
• W2075849809 cites W2093371959 @default.
• W2075849809 cites W2093613683 @default.
• W2075849809 cites W2097644281 @default.
• W2075849809 cites W2104501515 @default.
• W2075849809 cites W2113856817 @default.
• W2075849809 cites W2114383061 @default.
• W2075849809 cites W2115549126 @default.
• W2075849809 cites W2119351872 @default.
• W2075849809 cites W2121812224 @default.
• W2075849809 cites W2130522236 @default.
• W2075849809 cites W2130921495 @default.
• W2075849809 cites W2134659609 @default.
• W2075849809 cites W2138896702 @default.
• W2075849809 cites W2139073495 @default.
• W2075849809 cites W2142776762 @default.
• W2075849809 cites W2147960762 @default.
• W2075849809 cites W2156033360 @default.
• W2075849809 cites W2157824687 @default.
• W2075849809 cites W2158424267 @default.
• W2075849809 cites W2158563134 @default.
• W2075849809 cites W2163981356 @default.
• W2075849809 cites W2167344440 @default.
• W2075849809 cites W2280504235 @default.
• W2075849809 cites W2333538597 @default.
• W2075849809 cites W2339221030 @default.
• W2075849809 cites W2589957652 @default.
• W2075849809 doi "https://doi.org/10.1038/aps.2010.106" @default.
• W2075849809 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/4002297" @default.
• W2075849809 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/20694025" @default.
• W2075849809 hasPublicationYear "2010" @default.
• W2075849809 type Work @default.
• W2075849809 sameAs 2075849809 @default.
• W2075849809 citedByCount "43" @default.
• W2075849809 countsByYear W20758498092012 @default.
• W2075849809 countsByYear W20758498092013 @default.
• W2075849809 countsByYear W20758498092014 @default.
• W2075849809 countsByYear W20758498092015 @default.
• W2075849809 countsByYear W20758498092016 @default.
• W2075849809 countsByYear W20758498092017 @default.
• W2075849809 countsByYear W20758498092018 @default.
• W2075849809 countsByYear W20758498092019 @default.
• W2075849809 countsByYear W20758498092020 @default.
• W2075849809 countsByYear W20758498092021 @default.
• W2075849809 crossrefType "journal-article" @default.
• W2075849809 hasAuthorship W2075849809A5018692209 @default.
• W2075849809 hasAuthorship W2075849809A5019881260 @default.
• W2075849809 hasAuthorship W2075849809A5050339289 @default.
• W2075849809 hasAuthorship W2075849809A5050878902 @default.
• W2075849809 hasAuthorship W2075849809A5089011631 @default.
• W2075849809 hasBestOaLocation W20758498091 @default.

• next